Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers

Masanori Yoshimatsu, Gouji Toyokawa, Shinya Hayami, Motoko Unoki, Tatsuhiko Tsunoda, Helen I. Field, John D. Kelly, David E. Neal, Yoshihiko Maehara, Bruce A.J. Ponder, Yusuke Nakamura, Ryuji Hamamoto

Research output: Contribution to journalArticlepeer-review

197 Citations (Scopus)

Abstract

Protein arginine methylation is a novel post-translational modification regulating a diversity of cellular processes, including histone functions, but the roles of protein arginine methyltransferases (PRMTs) in human cancer are not well investigated. To address this issue, we first examined expression levels of genes belonging to the PRMT family and found significantly higher expression of PRMT1 and PRMT6, both of which are Type I PRMTs, in cancer cells of various tissues than in non-neoplastic cells. Abrogation of the expression of these genes with specific siRNAs significantly suppressed growth of bladder and lung cancer cells. Expression profile analysis using the cells transfected with the siRNAs indicated that PRMT1 and PRMT6 interplay in multiple pathways, supporting regulatory roles in the cell cycle, RNA processing and also DNA replication that are fundamentally important for cancer cell proliferation. Furthermore, we demonstrated that serum asymmetric dimethylarginine (ADMA) levels of a number of cancer cases are significantly higher than those of nontumor control cases. In summary, our results suggest that dysregulation of PRMT1 and PRMT6 can be involved in human carcinogenesis and that these Type I arginine methyltransferases are good therapeutic targets for various types of cancer.

Original languageEnglish
Pages (from-to)562-573
Number of pages12
JournalInternational Journal of Cancer
Volume128
Issue number3
DOIs
Publication statusPublished - Feb 1 2011

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers'. Together they form a unique fingerprint.

Cite this